{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/operationalizing-complex-rare-neuromuscular-clinical-trials#webpage",
"url": "https://www.fortrea.com/insights/operationalizing-complex-rare-neuromuscular-clinical-trials",
"name": "Operationalizing complex, rare neuromuscular clinical trials",
"description": "Explore how rare neuromuscular clinical trials require specialized approaches to patient recruitment, site selection, and endpoint assessment in complex rare disease settings. Learn how rare disease patient recruitment in clinical trials can be improved through targeted strategies that address small patient populations and geographic challenges. Explore how clinical trial site selection in rare disease studies and neuromuscular disorder clinical research support more effective study execution. Learn how endpoint assessments in neuromuscular trials and pediatric neuromuscular clinical studies help define meaningful outcomes and advance orphan drug development. By integrating recruitment strategies, site expertise, and tailored endpoint design, organizations can improve the success and efficiency of rare neuromuscular clinical trials."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Operationalizing complex, rare neuromuscular clinical trials",
"item": "https://www.fortrea.com/insights/operationalizing-complex-rare-neuromuscular-clinical-trials"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry - as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/operationalizing-complex-rare-neuromuscular-clinical-trials#article",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/operationalizing-complex-rare-neuromuscular-clinical-trials#webpage"
},
"headline": "Rare Neuromuscular Clinical Trials and Patient Recruitment Strategies | Fortrea Insights",
"description": "Explore how rare neuromuscular clinical trials require specialized approaches to patient recruitment, site selection, and endpoint assessment in complex rare disease settings. Learn how rare disease patient recruitment in clinical trials can be improved through targeted strategies that address small patient populations and geographic challenges. Explore how clinical trial site selection in rare disease studies and neuromuscular disorder clinical research support more effective study execution. Learn how endpoint assessments in neuromuscular trials and pediatric neuromuscular clinical studies help define meaningful outcomes and advance orphan drug development. By integrating recruitment strategies, site expertise, and tailored endpoint design, organizations can improve the success and efficiency of rare neuromuscular clinical trials.",
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2024-10-14",
"dateModified": "2024-10-14",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2024-10/AR_0008_Rare%20Neuromuscular_0624_HiRes.pdf",
"encodingFormat": "application/pdf"
}
}
]
}